TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up
Brief Summary: This study examined whether self-efficacy promoted adherence to Pelvic Floor Muscle Training (PFMT) and Bladder Training (BT) in women aged 55 and older.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-management; Assigned to Arm(s): N/A
B: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
C: Arm Label: 1 Bladder Health Class; Type: OTHER; Interventions: Behavioral: Bladder Health Class | Arm Label: 2 Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bladder Health Class; Assigned to Arm(s): 1 Bladder Health Class
D: Intervention Type: BEHAVIORAL; Name: Bladder Health Class consisting of 6 weekly group sessions; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Practice PFMT and BT; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Clinic examination for pelvic muscle function; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Record keeping in 3-day voiding diary; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up
Brief Summary: This study examined whether self-efficacy promoted adherence to Pelvic Floor Muscle Training (PFMT) and Bladder Training (BT) in women aged 55 and older.


Options:
A: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice
B: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP
C: Intervention Type: BEHAVIORAL; Name: Bladder Health Class consisting of 6 weekly group sessions; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Practice PFMT and BT; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Clinic examination for pelvic muscle function; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Record keeping in 3-day voiding diary; Assigned to Arm(s): N/A
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or placebo for acute gout flares.


Options:
A: Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Colchicine (for 1 month); Assigned to Arm(s): N/A
C: Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: High Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: High Dose Colchicine (4.8 mg total dose) | Arm Label: Low Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Low Dose Colchicine (1.8mg total dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Control | Intervention Type: DRUG; Name: High Dose Colchicine (4.8 mg total dose); Assigned to Arm(s): High Dose Colchicine | Intervention Type: DRUG; Name: Low Dose Colchicine (1.8mg total dose); Assigned to Arm(s): Low Dose Colchicine | Intervention Type: OTHER; Name: Placebo Control; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Placebo Controlled Trial Assessing the Effects of Ezopiclone on the Quality of Overnight Polysomnography and CPAP Titration
Brief Summary: Patients often have difficulty sleeping during overnight sleep testing in a lab environment. The purpose of this study is to determine if taking a sleep aid will improve sleep and therefore the quality of the sleep study.


Options:
A: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: zopiclone 7,5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): eszopiclone 3 mg | Intervention Type: DRUG; Name: Zopiclone; Assigned to Arm(s): zopiclone 7,5mg
C: Arm Label: PSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lunesta, Drug: Placebo control | Intervention Type: DRUG; Name: Lunesta; Assigned to Arm(s): PSG | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): PSG
D: Arm Label: Low dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: High dose eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): Low dose eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): High dose eszopiclone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled,Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody,When Administered to Adults With Mild Persistent Asthma
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg
B: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
C: Arm Label: MEDI528 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 0.3 mg/kg | Arm Label: MEDI528 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 1 mg/kg | Arm Label: MEDI528 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 3 mg/kg | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: BIOLOGICAL; Name: MEDI528 0.3 mg/kg; Assigned to Arm(s): MEDI528 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: MEDI528 1 mg/kg; Assigned to Arm(s): MEDI528 1 mg/kg | Intervention Type: BIOLOGICAL; Name: MEDI528 3 mg/kg; Assigned to Arm(s): MEDI528 3 mg/kg | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO
D: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics
Brief Summary: This study aims to enhance pediatric primary care to make it more responsive to psychosocial needs facing many families. We hypothesized that by identifying and addressing certain problems, such as depressed mothers, parental drug use, and domestic violence, we would help decrease child abuse and neglect.


Options:
A: Arm Label: Model Care (SEEK); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced pediatric primary care | Arm Label: Standard pediatric primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard pediatric primary care | Intervention Type: BEHAVIORAL; Name: Enhanced pediatric primary care; Assigned to Arm(s): Model Care (SEEK) | Intervention Type: BEHAVIORAL; Name: Standard pediatric primary care; Assigned to Arm(s): Standard pediatric primary care
B: Arm Label: advocacy intervention; Type: EXPERIMENTAL; Interventions: Behavioral: advocacy intervention | Arm Label: Usual community services; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual community services | Intervention Type: BEHAVIORAL; Name: advocacy intervention; Assigned to Arm(s): advocacy intervention | Intervention Type: BEHAVIORAL; Name: usual community services; Assigned to Arm(s): Usual community services
C: Intervention Type: PROCEDURE; Name: Woman Abuse Screening Tool; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Partner Violence Screen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Computerized screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Face to face screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Written screening on forms; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: Interactive computer based health-risk survey before doctor's visit; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics
Brief Summary: This study aims to enhance pediatric primary care to make it more responsive to psychosocial needs facing many families. We hypothesized that by identifying and addressing certain problems, such as depressed mothers, parental drug use, and domestic violence, we would help decrease child abuse and neglect.


Options:
A: Arm Label: NFP + IPV intervention; Type: EXPERIMENTAL; Interventions: Behavioral: NFP + IPV intervention | Arm Label: NFP (standard care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NFP + IPV intervention; Assigned to Arm(s): NFP + IPV intervention
B: Arm Label: Model Care (SEEK); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced pediatric primary care | Arm Label: Standard pediatric primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard pediatric primary care | Intervention Type: BEHAVIORAL; Name: Enhanced pediatric primary care; Assigned to Arm(s): Model Care (SEEK) | Intervention Type: BEHAVIORAL; Name: Standard pediatric primary care; Assigned to Arm(s): Standard pediatric primary care
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: RHANI Wives Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: RHANI WIves | Intervention Type: BEHAVIORAL; Name: RHANI WIves; Assigned to Arm(s): RHANI Wives Intervention
D: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics
Brief Summary: This study aims to enhance pediatric primary care to make it more responsive to psychosocial needs facing many families. We hypothesized that by identifying and addressing certain problems, such as depressed mothers, parental drug use, and domestic violence, we would help decrease child abuse and neglect.


Options:
A: Arm Label: Model Care (SEEK); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced pediatric primary care | Arm Label: Standard pediatric primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard pediatric primary care | Intervention Type: BEHAVIORAL; Name: Enhanced pediatric primary care; Assigned to Arm(s): Model Care (SEEK) | Intervention Type: BEHAVIORAL; Name: Standard pediatric primary care; Assigned to Arm(s): Standard pediatric primary care
B: Arm Label: Referral Card Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Integrated Screening; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Screening | Intervention Type: BEHAVIORAL; Name: Integrated Screening; Assigned to Arm(s): Integrated Screening
C: Intervention Type: BEHAVIORAL; Name: Prompting (survey instrument/resources list) (behavior); Assigned to Arm(s): N/A
D: Arm Label: NFP + IPV intervention; Type: EXPERIMENTAL; Interventions: Behavioral: NFP + IPV intervention | Arm Label: NFP (standard care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NFP + IPV intervention; Assigned to Arm(s): NFP + IPV intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma
Brief Summary: The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR) rate.


Options:
A: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
B: Arm Label: Thalidomide; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: Melphalan+Prednisolone | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan+Prednisolone | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide | Intervention Type: DRUG; Name: Melphalan+Prednisolone; Assigned to Arm(s): Control, Thalidomide
C: Arm Label: Arm I (thalidomide); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Melphalan, Drug: Prednisone, Other: Quality-of-Life Assessment, Drug: Thalidomide | Arm Label: Arm II (lenalidomide); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Drug: Melphalan, Drug: Prednisone | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Arm II (lenalidomide) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (thalidomide) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I (thalidomide)
D: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma
Brief Summary: The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR) rate.


Options:
A: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
B: Arm Label: Velcade-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Dexamethasone | Arm Label: Velcade-Thalidomide-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Thalidomide-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Dexamethasone; Assigned to Arm(s): Velcade-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Thalidomide-Dexamethasone; Assigned to Arm(s): Velcade-Thalidomide-Dexamethasone
C: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
D: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacogenetics, Emotional Reactivity and Smoking
Brief Summary: The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.


Options:
A: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: D